AM-1235

Source: Wikipedia, the free encyclopedia.
AM-1235
Legal status
Legal status
Identifiers
  • 1-[(5-Fluoropentyl)-6-nitro-1H-indol-3-yl]-(naphthalen-1-yl)methanone
JSmol)
  • c24ccccc2cccc4C(=O)c(c3)c1ccc([N](=O)=O)cc1n3CCCCCF
  • InChI=1S/C24H21FN2O3/c25-13-4-1-5-14-26-16-22(20-12-11-18(27(29)30)15-23(20)26)24(28)21-10-6-8-17-7-2-3-9-19(17)21/h2-3,6-12,15-16H,1,4-5,13-14H2 ☒N
  • Key:LNGVQORPSNNMSZ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

AM-1235 (1-(5-fluoropentyl)-3-(naphthalen-1-oyl)-6-nitroindole) is a drug that acts as a potent and reasonably selective agonist for the cannabinoid receptor CB1.

Pharmacology

Pharmacodynamics

AM-1235 is a

CB2.[1] While the 6-nitro substitution on the indole ring reduces affinity for both CB1 and CB2 relative to the unsubstituted parent compound AM-2201, CB2 affinity is reduced much more, resulting in a CB1 selectivity of around 13 times.[2] This is in contrast to other related compounds such as AM-1221 where a 6-nitro substitution instead confers significant selectivity for CB2.[3]

Pharmacokinetics

Main article: Pharmacokinetic data of JWH-018 are generally applicable to AM-1235.

AM-1235

fluoroalkane chains metabolize into substantially less toxic fluoropropanoic acid.[4][5]

Legal status

In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as AM-1235 are

Schedule I Controlled Substances.[6]

See also

References

  1. Makriyannis A
    , Deng H, "Cannabimimetic indole derivatives", published 2004-11-05, issued 2007-07-10     
  2. ProQuest 304624325
    .
  3. ^ WO granted 200128557, Makriyannis A, Deng H, "Cannabimimetic indole derivatives", published 2001-04-26, issued 2001-06-07 
  4. doi:10.1139/v56-200
    .
  5. doi:10.1139/v57-021
    .
  6. ^ 21 U.S.C. § 812: Schedules of controlled substances
Retrieved from "https://en.wikipedia.org/w/index.php?title=AM-1235&oldid=1087401987"